更新于：2024-11-21

Fenoterol Hydrobromide

氢溴酸非诺特罗

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

1-(3,5-dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane、1-(p-hydroxyphenyl)-2-((β-hydroxy-β-(3',5'-dihydroxyphenyl))ethyl)aminopropane、3,5-dihydroxy-α-(((p-hydroxy-α-methylphenethyl)amino)methyl)benzyl alcohol

+ [13]

靶点

β2-adrenergic receptor

作用机制

β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

免疫系统疾病感染呼吸系统疾病+ [1]

在研适应症

慢性支气管炎尘肺病肺气肿+ [2]

非在研适应症

慢性肺疾病

原研机构-

在研机构

Nippon Boehringer Ingelheim Co., Ltd.

University Medical Center Göttingen

非在研机构

Boehringer Ingelheim GmbH

最高研发阶段批准上市

首次获批日期

(1971-01-01),

哮喘慢性阻塞性肺疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C17H21NO4

InChIKeyLSLYOANBFKQKPT-UHFFFAOYSA-N

CAS号13392-18-2

查看全部结构式(2)

关联

项与氢溴酸非诺特罗相关的临床试验

ChiCTR2300071384 / SuspendedN/AIIT

A single center, randomized, open, placebo-controlled, parallel controlled clinical trial on the efficacy and safety of patchouli alcohol in the treatment of acute migraine

开始日期2023-05-22

申办/合作机构

广州医科大学第一附属医院

NCT05294965 / Completed早期临床1期IIT

Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue

The purpose of the study is to asses brown adipose tissue activity in humans after intravenous administration of the selective beta-2-adrenergic agonist fenoterol as compared to the natural activator of brown adipose tissue, a mild cold stimulus.

开始日期2022-04-27

申办/合作机构

Universitätsspital Basel

NCT03910985 / Unknown status临床4期IIT

Assessment of Reactance Parameters Measured by the Forced Oscillation Technique for the Bronchodilator Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

The aims of this study is :
to assess the bronchodilator (DUOVENT HFA) response of parameters measured by the forced oscillations (FOT) and in particular the reactance parameters related to the presence of a limitation of expiratory flows
to compare the response of the reactance parameters to bronchodilators with the conventional spirometric parameters (FEV1) and inspiratory capacity (IC), and according to the severity of the disease
to assess and compare the relationship between the response to bronchodilators in terms of IC on the one hand and on the other hand in terms of FEV1, reactance parameters (measured by FOT), resistance parameters (measured by plethysmography and FOT)
Assess and compare the relationship between dyspnea intensity assessed by various scales and conventional respiratory function parameters (spirometry, plethysmography, diffusion indices) and parameters measured by FOT

开始日期2019-04-23

申办/合作机构-

100 项与氢溴酸非诺特罗相关的临床结果

登录后查看更多信息

100 项与氢溴酸非诺特罗相关的转化医学

登录后查看更多信息

100 项与氢溴酸非诺特罗相关的专利（医药）

登录后查看更多信息

1,684

项与氢溴酸非诺特罗相关的文献（医药）

2024-09-01·Molecular Neurobiology

β2-Adrenergic Regulation of the Neuromuscular Transmission and Its Lipid-Dependent Switch

Article

作者: Petrov, Alexey M ; Fedorov, Nikita S ; Khaziev, Arthur N ; Tsentsevitsky, Andrei N ; Gafurova, Chulpan R ; Malomouzh, Artem I

β2-Adrenoceptors (β2-ARs) are the most abundant subtype of adrenergic receptors in skeletal muscles. Their activation via a stabilization of postsynaptic architecture has beneficial effects in certain models of neuromuscular disorders. However, the ability of β2-ARs to regulate neuromuscular transmission at the presynaptic level is poorly understood. Using electrophysiological recordings and fluorescent FM dyes, we found that β2-AR activation with fenoterol enhanced an involvement of synaptic vesicles in exocytosis and neurotransmitter release during intense activity at the neuromuscular junctions of mouse diaphragm. This was accompanied by an improvement of contractile responses to phrenic nerve stimulation (but not direct stimulation of the muscle fibers) at moderate-to-high frequencies. β2-ARs mainly reside in lipid microdomains enriched with cholesterol and sphingomyelin. The latter is hydrolyzed by sphingomyelinases, whose upregulation occurs in many conditions characterized by muscle atrophy and sympathetic nerve hyperactivity. Sphingomyelinase treatment reversed the effects of β2-AR agonist on the neurotransmitter release and synaptic vesicle recruitment to the exocytosis during intense activity. Inhibition of G_i protein with pertussis toxin completely prevented the sphingomyelinase-mediated inversion in the β2-AR agonist action. Note that lipid raft disrupting enzyme cholesterol oxidase had the same effect on β2-AR agonist-mediated changes in neurotransmission as sphingomyelinase. Thus, β2-AR agonist fenoterol augmented recruitment and release of synaptic vesicles during intense activity in the diaphragm neuromuscular junctions. Sphingomyelin hydrolysis inversed the effects of β2-AR agonist on neurotransmission probably via switching to G_i protein-dependent signaling. This phenomenon may reflect a dependence of the β2-AR signaling on lipid raft integrity in the neuromuscular junctions.

2024-07-01·Chemosphere

Non-target metabolomics approach for the investigation of the hidden effects induced by atrazine and its degradation products on plant metabolism

Article

作者: Malejka, Anna ; Barchanska, Hanna ; Płonka, Joanna

Japanese radish (Raphanus sativus var. longipinnatus) plants grown under laboratory conditions were individually exposed to the same doses of atrazine (2-chloro-4-ethylamino-6-isopropylamino-1,3,5-triazine, ATR) or its main degradation products: either 2-amino-4-chloro-6-isopropylamino-1,3,5-triazine (DEA) or 2-amino-4-chloro-6-ethylamino-1,3,5-triazine (DIA) or desethyl-desisopropyl-atrazine (DEDIA) or 4-(ethylamino)-2-hydroxy-6-(isopropylamino)-1,3,5-triazine (HA), respectively. One week after treatment in plants exposed to ATR, DIA, and DEA, their concentrations were 7.8 μg/g, 9.7 μg/g, and 14.5 μg/g, respectively, while those treated with DEDIA and HA did not contain these compounds. These results were correlated with plant amino acid profile obtained by suspect screening analysis and metabolomic "fingerprint" based on non-target analysis, obtained by liquid chromatography coupled with QTRAP triple quadrupole mass spectrometer. In all cases, both ATR and its by-products were found to interfere with the plant's amino acid profile and modify its metabolic "fingerprint". Therefore, we proved that the non-target metabolomics approach is an effective tool for investigating the hidden effects of pesticides and their transformation products, which is particularly important as these compounds may reduce the quality of edible plants.

2023-12-01·Chinese Journal of Chromatography

Determination of 14 <italic>β</italic>-agonists in animal meat by ultra high performance liquid chromatography-tandem mass spectrometry

Article

作者: Wang, Xuesong ; Li, Ning ; Xiao, Jin ; Zhou, Xin ; Kang, Junjie ; Dong, Jieqiong

The addition of β-agonists to animal feed can significantly improve the lean-meat rate of pigs, cattle, sheep, and other animals. However, the food residues of β-agonists are harmful to human health. When meat with β-agonist residues is consumed, poisoning symptoms such as palpitation, dizziness, and muscle tremors may develop, and damage to the cardiovascular system, liver, and kidney may occur. In this study, a method based on ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was established for the rapid detection of 14 β-agonists (clenbuterol, salbutamol, ractopamine, clorprenaline, terbutaline, tulobuterol, bromobuterol, bambuterol, zilpaterol, mabuterol, fenoterol, arformoterol, cimaterol, and cimbuterol) in animal food sources. The sample pretreatment method and chromatographic conditions were optimized. The samples were hydrolyzed with β-glucuronidase hydrochloride/aryl sulfate esterase in ammonium acetate buffer (pH 5.2). Enzymatic hydrolysis was performed in a constant-temperature water bath ((36±2) ℃) oscillator for 16 h. The samples were cooled to room temperature and extracted with 0.5% formic acid acetonitrile. NaCl was added to separate the organic and aqueous phases, and 5 mL of the upper organic layer was purified using a one-step purification solid-phase extraction column. After drying with nitrogen at 50 ℃, the residue was dissolved in 0.4 mL of 0.2% formic acid aqueous solution. The samples were passed through a 0.22 μm filter and detected by UHPLC-MS/MS with gradient elution using acetonitrile and 0.1% formic acid aqueous solution as the mobile phases. The analytes were separated on a Phenomenex Kinetex F5 column and detected by positive-ion scanning in multiple-reaction monitoring (MRM) mode. Internal and external standard methods were used for quantitative analysis. The effects of the extract pH, solid-phase extraction column, purification method, and dissolved solution on the extraction efficiency were optimized during pretreatment. UHPLC-quadrupole time-of-flight MS was used to verify the purification effect of the one-step purification solid-phase extraction column, and the results indicated that this type of column could remove most of the phospholipids, sphingolipids, and glycerides in the sample extract. The factors influencing the different chromatographic columns and mobile phases were investigated. MS scanning was conducted in positive-ion mode with needle pump injection in mass-only mode, and the two daughter ions with the highest responses for each target were selected as the quantitative and qualitative ions. The declustering potential (DP) and collision energy (CE) of each ion were separately optimized in MRM mode. The switching mode of the mass spectrum and waste liquid was used, and the mobile phase was switched to waste liquid after all the target peaks were removed. These steps ensured that impurities in the sample flowed out of the column in a timely manner and that the effects of excessive impurities on the mass spectra were avoided. The 14 β-agonists showed good linear relationships in the range of 1.0-50 μg/L, with correlation coefficients of >0.99. The limits of detection (LODs) and quantification (LOQs) were in the range of 0.1-0.2 and 0.3-0.6 μg/kg, respectively. The average recoveries of the 14 β-agonists ranged from 70.25% to 117.48%, with relative standard deviations (RSDs) in the range of 0.63%-14.29% at low, medium, and high spiked levels. Pork, beef, and mutton samples were selected and analyzed using the developed method. The results were close to those of the national standard method, indicating that the method is accurate and reliable. Moreover, the proposed method has good stability and high accuracy; thus, it is suitable for the qualitative and quantitative determination of β-agonists in animal meat.

项与氢溴酸非诺特罗相关的新闻（医药）

2023-09-07

·Coatings World

OQ Chemicals Launches Oxbalance TCD Alcohol DM Made With Bio-circular DCPD From Shell Chemical

In response to growing market preferences for environmentally friendly alternatives, the global chemical company OQ Chemicals is ready to supply ISCC PLUS certified Oxbalance TCD Alcohol DM (tricyclodecane dimethanol). This product is manufactured using the bio-circular precursor DCPD (dicyclopentadiene) from Shell Chemicals Europe, which is also ISCC Plus certified. The strategic collaboration between the two companies will ensure a reliable supply of bio-circular DCPD to support OQ Chemicals’ production. TCD Alcohol DM serves as a versatile component in the production of high-performance technical polymers, paints and coatings, and adhesives used across sectors such as food packaging, electronics, and automotive. It is valued for its exceptional ability to enhance the properties of the final product, including improved durability, chemical resistance, and thermal stability. The bio-based Oxbalance TCD Alcohol DM serves as a sustainable and environmentally conscious alternative to its fully synthetic counterpart. “OQ Chemicals’ new Oxbalance offering aligns with changing market preferences as customers increasingly seek out more sustainable alternatives without compromising quality or performance. Our partnership with Shell Chemicals Europe ensures a consistent supply of high-quality bio-circular DCPD for our production. With Oxbalance TCD Alcohol DM, we’ve added another product to our portfolio that supports our customers on their path towards more sustainability,” said Kyle Hendrix, Executive Vice President Marketing at OQ Chemicals. “Our collaboration with OQ Chemicals to deliver ISCC PLUS-certified bio-circular DCPD that is based on a mass balance approach is another example of how Shell Chemicals works with customers to develop solutions to meet their objectives,” said Liz Allen, Director, Shell Chemicals Europe. “It’s also an example of how Shell is committed to delivering premium quality sustainable solutions to support a circular economy.” OxBalance is a registered trademark of OQ Chemicals. The mass balance method allocates renewable feedstock in manufacturing. ISCC PLUS certification by the International Sustainability & Carbon Certification organization confirms environmentally responsible sourcing and strict sustainability compliance.

2022-05-31

·丁香园

雾化吸入都能加生理盐水稀释吗？这几种药不要多此一举！

临床常用的雾化吸入药物主要有吸入性糖皮质激素（ICS）、短效 β2 受体激动剂（SABA）短效胆碱 M 受体拮抗剂（SAMA）和黏液溶解剂等几大类。实际用药中常存在两种或两种以上药物混合后雾化使用的情况，使用前应评估不同药物联合雾化的配伍相容性，以及对雾化装置最大容量和雾化时间的要求。下面，我们就常用雾化药物和生理盐水的配伍说明进行整理，供大家参考。一常用雾化药物和生理盐水的配伍说明1. 吸入用布地奈德混悬液可加入盐水，未强烈推荐。✦可与 0.9% 的氯化钠溶液和/或含特布他林，沙丁胺醇，非诺特罗，乙酰半胱氨酸，色甘酸钠或异丙托溴铵的雾化液混合。应在混合后 30 分钟内使用。✦对大多数雾化器，适当的药液容量为 2 ~ 4 mL。用法用量：2. 吸入用丙酸倍氯米松混悬液未明确说明。✦单剂量药瓶经雾化器给药。使用前充分摇匀，将所需药量挤入雾化器中。用法用量：3. 丙酸氟替卡松雾化吸入用混悬液推荐加入盐水稀释。✦需要时请用氯化钠注射液进行稀释。✦为确保混悬液更好地吸入或延长药物吸入的时间，可在用药前即刻用氯化钠注射液将其进行稀释。用法用量：4. 硫酸特布他林雾化吸入用溶液未明确说明。✦将小瓶中溶液挤入雾化器贮液器中。✦本品雾化液不可与碱性溶液即 pH 大于 7 的溶液混合。用法用量：5. 硫酸沙丁胺醇雾化吸入溶液根据剂量选择是否稀释。用法用量：6. 吸入用异丙托溴铵溶液可以加盐水稀释，未强烈推荐。✦单剂量小瓶中每 1 ml 雾化吸入液可用生理盐水稀释至终体积 2 ~ 4 mL。✦可以和祛痰剂盐酸氨溴索（沐舒坦）雾化吸入液、盐酸溴己新（Bisolvon）雾化吸入液和非诺特罗（Berotec）雾化吸入液共同吸入使用。✦因为可出现沉淀，与含有防腐剂苯扎氯铵的色苷酸钠雾化吸入液不要在同一个雾化器中同时吸入使用。用法用量：7. 吸入用复方异丙托溴铵溶液不推荐加入。✦不需要和任何其他雾化吸入溶液制剂混合。✦建议不需要将本品与其他药物混合在同一雾化器中使用。用法用量：8. 吸入用乙酰半胱氨酸未明确说明。用法用量：9. 吸入用盐酸氨溴索溶液必须加盐水稀释。✦本品应与 0.9% 氯化钠注射液按 1:1 比例混合使用以获得最佳加湿空气。✦可与 β-拟交感神经药、吸入用异丙托溴铵溶液混合使用，但不得与色甘酸钠混用。✦应避免与导致混合溶液 pH 高于 6.3 的药物混合使用，以防止 pH 升高导致游离氨溴索失效或溶液浑浊。用法用量：二关于雾化药物的几个注意事项说明雾化吸入治疗除了注意药物配制时的配伍禁忌，也要注意各种药物不良反应。其不良反应程度与类型各不相同，与患者本身因素、雾化吸入不规范、雾化治疗药物副作用以及非雾化剂型不合理使用等因素有关。✦ ICS 常见局部不良反应，见下表：✦ 几种吸入性支气管舒张剂的常见不良反应，见下表：✦ 以下这 3 种不良反应需特别说明，以引起大家的重视：NO1. 低钾血症沙丁胺醇和特布他林等药物不良反应包括低血钾、心律紊乱等。患有急性重症哮喘的患者在应用沙丁胺醇和特布他林时应特别小心，本品在与黄嘌呤衍生物、肾上腺糖皮质激素、利尿剂合并用药时，或在缺氧状态下给药时，可能会出现上述作用。建议在此种情况中监测血清钾浓度。低钾血症可增加心律失常的倾向。因为低钾血症也会增加洋地黄中毒风险，因此建议特别关注接受毛地黄糖苷治疗的患者。NO2. 血糖异常SABA 可增加高血糖风险。吸入用硫酸沙丁胺醇会引起可逆性代谢改变，例如血糖浓度升高现象。糖尿病患者对这种血糖增高有可能无力代偿，曾有发展成酮症酸中毒的报道。同时使用肾上腺糖皮质激素可加剧上述作用。建议对伴有糖尿病患者在开始使用沙丁胺醇、特布他林时应监测血糖。对妊娠糖尿病患者，需特别注意高血糖和酮症酸中毒风险增加。胰岛素剂量因此可能需要调整。NO3. 支气管痉挛和其他吸入治疗一样，雾化吸入用药后患者可能会立即出现反常的支气管痉挛。如发生严重反应，必须对治疗进行重新评估，如有需要，制定替代治疗方案。布地奈德与其它吸入性哮喘药同时使用时，可能出现支气管痉挛，并伴有哮鸣的即时性加重。如果在吸入用布地奈德混悬液给药后出现了急性支气管痉挛，必须马上使用一种速效吸入性支气管扩张剂进行治疗，中断吸入用布地奈德混悬液治疗，并且采取其它替代治疗方案。同样，如患者使用沙丁胺醇雾化剂时出现气喘加重，应马上采用其他给药方法或吸入另一种速效的支气管扩张剂。另外布地奈德不是支气管扩张剂，因而不应用于快速缓解急性支气管痉挛或者其它哮喘急性发作。哮喘急性发作期可雾化吸入速效 β2 受体激动剂（SABA）和 ICS，慎用其他祛痰药物。策划：美超投稿：wangmeichao@dxy.cn题图：站酷海洛参考文献1. 中华医学会呼吸病学分会. 雾化祛痰临床应用的中国专家共识. 中华结核和呼吸杂志，2021，44（4）.2. 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南（2020 年版）. 中华结核和呼吸杂志，2020，43（12）.

2021-06-17

·Composites World

Basaltex reveals basalt fiber milestone for use in rail carriage interiors

Photo Credit: Basaltex NV Basalt fibers company Basaltex NV (Wevelgem, Belgium) reports that it has achieved a significant milestone in developing and testing a new composite material solution for railway applications comprising basalt fibers with EconCore’s (Leuven, Belgium) patented honeycomb technology. Combining basalt fibers (extrudable at a temperature of 1,450ºF), a polyfurfuryl alcohol bioresin — 100% derived from sugarcane waste — and recycled polyethylene terephthalate (rPET), Basaltex says the new material development has greatly improved fire resistance, and is highly rigid. This is in addition to lightweighting properties from the honeycomb, a drastic weight reduction compared to traditional monothilic glass fiber-reinforced polymers (GFRP) used in train interiors, the company notes. This combination also makes the final product sustainable and environmentally friendly, unlike a majority of thermoset solutions in this type of application. Such sandwich panel could be deployed in applications such as cladding panels, partitions, tables and flooring. The thermoset skin layers provide a fast cure at elevated temperature for short cycle times and potential automated production capabilities. As well as the railway interior application, Basaltex says this new material combination could be used in any application that requires fire performance combined with a low weight. “Honeycomb and stone? Some combinations don’t automatically come to mind, but this material solution could enable converters to combine fire safety, lightweighting and sustainability in an elegant way,” says Jef Delbroek, project engineer at EconCore. “We look forward to seeing how the railway industry will respond to this novel material combination and hope to arouse interest of other industries as well.”

100 项与氢溴酸非诺特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01428	氢溴酸非诺特罗	R03AC04 G02CA03 R03CC04	DB01288

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性支气管炎	日本	Nippon Boehringer Ingelheim Co., Ltd.	1999-03-15
尘肺病	日本	Nippon Boehringer Ingelheim Co., Ltd.	1999-03-15
肺气肿	日本	Nippon Boehringer Ingelheim Co., Ltd.	1999-03-15
哮喘	-	-	1971-01-01
慢性阻塞性肺疾病	-	-	1971-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床1期	-	Boehringer Ingelheim GmbH	1990-02-01
慢性肺疾病	临床前	荷兰	Boehringer Ingelheim GmbH	2002-10-01
慢性阻塞性肺疾病	临床前	荷兰	Boehringer Ingelheim GmbH	2002-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ERS2014	N/A	阻塞性肺疾病	42	Fenoterol	(網鑰顧獵衊願選鹽膚鑰) = 餘簾窪壓壓壓艱鬱壓選壓築遞憲築觸鹽願網蓋 (鹹艱遞齋淵鑰製顧糧願 )	积极	2014-09-01
				Ipratropium	(網鑰顧獵衊願選鹽膚鑰) = 簾鑰糧憲願簾餘鏇窪願壓築遞憲築觸鹽願網蓋 (鹹艱遞齋淵鑰製顧糧願 )
NCT00274066 (Pubmed \| Chest)	临床3期	慢性阻塞性肺疾病 \| 慢性肺疾病维持 \| 追加	60	Ipratropium bromide	醖廠鬱築醖醖鑰鹹製壓(壓窪構襯艱鏇網鹽製壓) = 鑰襯膚繭鬱鏇遞齋齋觸願襯憲膚構蓋獵觸醖鹽 (壓簾廠構膚糧衊遞鹽淵 )	-	2007-11-01
				Fenoterol	醖廠鬱築醖醖鑰鹹製壓(壓窪構襯艱鏇網鹽製壓) = 膚構齋醖構範淵鬱選鑰願襯憲膚構蓋獵觸醖鹽 (壓簾廠構膚糧衊遞鹽淵 )